WARF Advances in Health Care | October 2024

WARF ADVANCES
Top licensing prospects from the University of Wisconsin-Madison

WT-7695 Achieved 100% Survival at 1 mCi in a Model of Kidney Cancer
UW-Madison researchers have developed a novel compound with best-in-class properties (in vivo tumor uptake, retention and efficacy) for treating CAIX cancers.
Read more

Synthetic Biomolecule Promotes T Cell Proliferation and Tumoricidal Effects
This biological therapeutic - created by fusing the cytokines IL-6 and IL-1β - stimulates the immune system to fight solid tumors.
Read more

Image Analysis of Histologically Normal Prostate Biopsies Predicts Cancer Presence
This simple, rapid and quantitative imaging-based method can be used for the accurate diagnosis and prognosis of prostate cancer.
Read more

Novel Cereblon E3 Ligase Ligands
UW pharmaceutical scientists developed a novel class of molecules that bind cereblon (CRBN), a ubiquitin ligase, and may be used in the development of PROTAC therapeutics.
Read more

Predicting Responses to Disease Treatments
This novel method, called TARGETS (TreAtment Response Generalized Elastic-neT Signatures), predicts optimal treatment responses in oncology patients based on DNA and RNA sequences in circulating tumor cells.
Read more

Automatic In Vitro Diagnostic Medical Device for Intraventricular Drainage
UW-Madison researchers have developed a digitally controlled cerebrospinal fluid (CSF) drainage device for use in ICU settings that provides improved precision and safety.
Read more

Read about more licensing prospects!

Featured UW-Madison Researcher

In the News

Public link

Please use the above public link if you want to share this noodl on another website.